Benefits
Modest urinary symptom improvement, studied in men with BPH
A 2000 meta-analysis pooling 18 randomized trials in 1,562 men who had already been diagnosed with BPH found that pygeum modestly but significantly improved urinary symptom scores compared with placebo, with about 19% less night-time urination and about 23% better peak urine flow. The 2002 Cochrane review of the same evidence agreed that pygeum may be a useful option, and added that the trials were small, short, used varied doses and preparations, and rarely used standardized validated symptom measures. Every one of these studies was done in men with a diagnosed prostate condition, so this is not a description of what pygeum does for a healthy prostate, and pygeum should not be treated as a therapy for BPH. Anyone with urinary symptoms should be evaluated by a doctor first.
Night-time urination: about 19% fewer episodes in pooled trials of men with BPH
In the pooled older trials of men with BPH, night-time urination fell by roughly 19% more with pygeum than with placebo. That is a modest average change, and Cochrane described the underlying trials as small, short and inconsistent in how they measured symptoms, so 'validated' overstates it. Waking at night to urinate has many possible causes, so it is worth being checked by a doctor rather than assuming an enlarged prostate.
Urinary flow rate improvement
Peak urine flow was about 23% better than placebo when the older trials in men with BPH were pooled. None of the studies cited on this page compared pygeum head to head with an alpha-blocker or any other prescription medicine, so no claim can be made about which works better or which is safer. What the reviews do report is that side effects with pygeum were mild and similar to placebo.
Sexual side effects: not compared head to head with prostate medicines
None of the four studies cited on this page compared pygeum with finasteride or dutasteride, so no advantage over those medicines can be claimed here. What the cited reviews report is that side effects with pygeum were mild and no more common than with placebo, and sexual side effects were not flagged as a problem in those trials. Never stop or change a prescribed prostate medicine in order to take a supplement.
Proposed mechanisms, from lab studies rather than from people
The explanations offered for pygeum's effects come from laboratory and animal work, not from the human trials cited here: anti-inflammatory activity in prostate tissue, effects on growth factor signalling (FGF, EGF), reduced fibroblast growth, and weak inhibition of the 5-alpha-reductase enzyme. These remain hypotheses about how it might work. None of them were measured in the men who took part in the cited trials.
BPH is not prostate cancer — important context
BPH is a benign (non-cancerous) enlargement of the prostate. Pygeum has not been shown to prevent or treat prostate cancer, and it is not a treatment for BPH either. BPH and prostate cancer are distinct conditions despite similar symptoms. None of the studies cited on this page measured PSA, so nothing here can say what pygeum does or does not do to a PSA reading. Weak stream, urgency and night-time urination can be caused by prostate cancer, infection or other conditions as well as by BPH, so anyone with new or worsening urinary symptoms needs a doctor's assessment. A supplement must never delay that.
CITES Appendix II listing: a sourcing issue, not a health benefit
Wild Prunus africana is listed under CITES Appendix II, which means international trade requires permits to keep over-harvesting from wiping out the species. Choose products with documented sustainable sourcing (plantation-grown or certified sustainable wild-harvest). Some manufacturers use bark from plantation-grown trees in Cameroon and Madagascar. This is an environmental sourcing question and has nothing to do with how well the supplement works.
Mechanism of action
Modest 5α-reductase inhibition
Pygeum extracts inhibit 5α-reductase (the enzyme converting testosterone to dihydrotestosterone, DHT) — the same enzyme target as finasteride and dutasteride. However, pygeum's inhibition is much weaker (in vitro IC50 in micromolar range vs. nanomolar for finasteride). That comparison comes from test-tube work. The human trials cited on this page did not measure DHT, prostate tissue or hormone levels, so how much of pygeum's effect comes from this enzyme is unknown.
Anti-inflammatory via 5-lipoxygenase pathway
In laboratory studies, pygeum extract inhibits 5-lipoxygenase (5-LOX) and reduces leukotriene B4 (LTB4) production in prostate tissue. Chronic prostatic inflammation contributes to BPH progression and symptoms; the 5-LOX pathway is a distinct anti-inflammatory mechanism complementing the modest 5α-reductase effect. Different from NSAID cyclooxygenase inhibition — leukotrienes mediate different inflammatory cascades.
Growth factor inhibition (bFGF, EGF, IGF-1)
In vitro studies show pygeum extracts inhibit basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), and insulin-like growth factor 1 (IGF-1) stimulation of prostate stromal cell proliferation. BPH involves fibromuscular stromal proliferation (not just glandular hyperplasia); growth factor inhibition addresses this stromal component. Whether any of this happens in men taking the supplement is unknown, because these were cell studies rather than human ones.
Bladder detrusor function effects
Pygeum extracts have direct effects on bladder detrusor muscle function in animal models — improving contractile efficiency and bladder emptying. BPH symptoms reflect both prostatic obstruction and secondary detrusor dysfunction (bladder muscle changes from chronic outlet obstruction). These bladder effects were seen in animals, so they remain a possible explanation rather than something shown in men.
Active compounds — the four-fraction complex
Standardized pygeum extract contains four bioactive fractions: phytosterols (β-sitosterol primary, contributes anti-inflammatory and 5α-reductase modulation); pentacyclic triterpenes (ursolic and oleanolic acids — primary anti-edema effects on prostate); ferulic acid esters (n-tetracosanol, n-docosanol — anti-androgenic); and tannins. No single compound has been shown to reproduce the effect of the whole extract, and the human trials all used a standardized lipophilic bark extract rather than isolated beta-sitosterol or any single fraction.
Clinical trials
Authors: Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G — Minneapolis VA Center for Chronic Disease Outcomes Research / Cochrane Review Group in Prostate Diseases and Urologic Malignancies.
1,562 men already diagnosed with symptomatic BPH, pooled across 18 randomized trials
Authors: Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G — Minneapolis VA Center for Chronic Disease Outcomes Research / Cochrane Review Group in Prostate Diseases and Urologic Malignancies. 18 randomized trials in 1,562 men with symptomatic BPH met inclusion criteria (clinical trial design, ≥30 days duration, pygeum monotherapy or combination vs. placebo or other BPH therapy). Pooled findings: pygeum produced statistically significant improvement in urologic symptom scores, nocturia (~19% reduction), peak urinary flow rate (~23% improvement vs placebo), and residual urine volume (~24% reduction). Adverse effects were mild and similar to placebo. Authors caveats: most trials predated modern reporting standards, sample sizes were modest, durations were short (30-122 days), and study quality varied. The authors' own conclusion was that a standardized preparation of Pygeum africanum may be a useful treatment option for men with lower urinary symptoms consistent with BPH, and that the reviewed studies were small in size, of short duration, used varied doses and preparations, and rarely reported outcomes using standardized validated measures. This is research in men with a diagnosed condition, not a description of what pygeum does for a healthy prostate.
Predecessor to the 2002 Cochrane review by the same Minneapolis VA group.
1,562 men
Predecessor to the 2002 Cochrane review by the same Minneapolis VA group. Pooled 18 randomized trials in 1,562 men with BPH, not all of which used a placebo comparison; some compared pygeum with other BPH therapy. Men taking pygeum were more than twice as likely to report overall symptom improvement vs. placebo. Nocturia decreased by ~19%, peak urinary flow improved by ~23%, residual urine volume decreased by ~24%. Side effects mild and similar to placebo. The two reviews are essentially the same evidence base analyzed by the same investigators in different formats.
Randomized double-blind comparison of pygeum 50 mg BID vs.
209 men
Chatelain C, Autet W, Brackman F. Randomized double-blind comparison of pygeum 50 mg BID vs. 100 mg once daily, with long-term open-label extension, in 209 men with BPH. This study compared two dosing schedules against each other and had no placebo group, so improvement seen in both arms cannot be credited to pygeum with any confidence. What it does show is that once-daily and twice-daily dosing performed similarly. All 209 participants were men under urological care for BPH.
Pygeum is often combined with nettle root in European prostate phytotherapy products.
No population: no combination trial is actually cited on this page.
Pygeum is often sold combined with nettle root or saw palmetto. None of the four studies cited on this page tested those combinations, and the trials this card originally named are not among the references listed. Treat combination products as untested by the evidence shown here: what was actually studied was pygeum bark extract on its own, in men with BPH.